keyword
MENU ▼
Read by QxMD icon Read
search

SSRIs

keyword
https://www.readbyqxmd.com/read/28730851/agomelatine-for-the-treatment-of-generalized-anxiety-disorder
#1
Massimiliano Buoli, Silvia Grassi, Marta Serati, A Carlo Altamura
Agomelatine is a melatonergic antidepressant, approved for the treatment of Major Depressive Disorder (MDD) in Europe and Australia, but not in the United States. This compound seems to be promising in the short-term and maintenance treatment of Generalized Anxiety Disorder (GAD). Areas covered: This paper presents an evaluation of the available data about the clinical efficacy and tolerability of agomelatine in the treatment of GAD. Expert opinion: First-line GAD treatments are limited by high rates of lack of clinical response...
July 21, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28730460/impact-of-safety-warnings-on-domperidone-prescribing-in-ireland
#2
M Teeling, M J MacAvin, K Bennett
AIM: This study aimed to investigate the impact of the 2014 safety warnings on use of domperidone, on subsequent prescribing patterns in Ireland. METHODS: The Irish HSE-PCRS pharmacy claims database was used to identify the study cohort (aged 18+), prescribed domperidone from Jan 2014 to Oct 2015. Dosage was available for each claim; concomitant prescription with the following drug classes was identified and calculated as a percentage of the total number of claims: anti-arrhythmics, macrolide antimicrobials and the selective serotonin receptor inhibitors (SSRIs) citalopram and escitalopram...
July 20, 2017: Irish Journal of Medical Science
https://www.readbyqxmd.com/read/28721535/tricyclic-and-tetracyclic-antidepressants-for-the-prevention-of-frequent-episodic-or-chronic-tension-type-headache-in-adults-a-systematic-review-and-meta-analysis
#3
Jeffrey L Jackson, Josephine M Mancuso, Sarah Nickoloff, Rebecca Bernstein, Cynthia Kay
BACKGROUND: Tension-type headaches are a common source of pain and suffering. Our purpose was to assess the efficacy of tricyclic (TCA) and tetracyclic antidepressants in the prophylactic treatment of tension-type headache. METHODS: We searched the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, the ISI Web of Science, and clinical trial registries through 11 March 2017 for randomized controlled studies of TCA or tetracyclic antidepressants in the prevention of tension-type headache in adults...
July 18, 2017: Journal of General Internal Medicine
https://www.readbyqxmd.com/read/28720356/phosphodiesterase-type-5-inhibitors-for-premature-ejaculation-a-systematic-review-and-meta-analysis
#4
REVIEW
Marrissa Martyn-St James, Katy Cooper, Shijie Ren, Eva Kaltenthaler, Kath Dickinson, Anna Cantrell, Kevan Wylie, Leila Frodsham, Catherine Hood
CONTEXT: Phosphodiesterase type 5 inhibitors (PDE5-Is) are prescribed off-label for the treatment of premature ejaculation (PE). OBJECTIVE: To systematically review the evidence from randomised controlled trials (RCTs) for PDE5-Is in the management of PE. EVIDENCE ACQUISITION: Medline and other databases were searched through September 2015. Quality of RCTs was assessed. Intravaginal ejaculatory latency time (IELT) data were pooled in a meta-analysis...
February 2017: European Urology Focus
https://www.readbyqxmd.com/read/28718394/multiple-possible-inaccuracies-cast-doubt-on-a-recent-report-suggesting-selective-serotonin-reuptake-inhibitors-to-be-toxic-and-ineffective
#5
Fredrik Hieronymus, Alexander Lisinski, Jakob Näslund, Elias Eriksson
According to a systematic review on the use of selective serotonin reuptake inhibitors (SSRIs) in adult depression that was recently published in BMC Psychiatry, the results of which have been widely disseminated in lay media, these drugs increase the risk for serious adverse events (SAEs) while exerting poor antidepressant efficacy. A cursory analysis, however, suggests the analysis of SAEs conducted by the authors to be marred by both methodological inaccuracies and blatant errors. After having corrected for these apparent mistakes, we conducted a sensitivity analysis in which we also accounted for a possible moderating effect of age; while this suggests SSRIs to be safe drugs in the non-elderly, they do confirm what is already known, that is, that they may enhance the risk for SAEs in the old...
July 18, 2017: Acta Neuropsychiatrica
https://www.readbyqxmd.com/read/28714608/selective-serotonin-reuptake-inhibitors-during-pregnancy-do-we-have-now-more-definite-answers-related-to-prenatal-exposure
#6
REVIEW
Asher Ornoy, Gideon Koren
Despite extensive studies, there still seems to be uncertainty as to the possible reproductive risk of selective serotonin reuptake inhibitors (SSRIs) and selective serotonin norepinephrine reuptake inhibitors (SNRIs) in pregnancy. We, therefore, assess the current data on the risk/benefit of SSRI use in pregnancy. As the neurodevelopmental effects of SSRIs are discussed in another paper in this issue, we will not address the possible neurodevelopmental effects. Special emphasis is given to the newer, large population-based studies...
July 17, 2017: Birth defects research
https://www.readbyqxmd.com/read/28714603/variations-in-neurodevelopmental-outcomes-in-children-with-prenatal-ssri-antidepressant-exposure
#7
REVIEW
Naama Rotem-Kohavi, Tim F Oberlander
Mood disorders and treatment with selective serotonin reuptake inhibitor (SSRI) antidepressants during pregnancy are common and both pose neurodevelopmental risks. This often makes the decision to treat prenatal depression with pharmacotherapy (i.e., antidepressants) challenging for clinicians and mothers. SSRIs block the reuptake of the neurotransmitter serotonin (5HT) and given its developmental role, it is not inconceivable that early changes in 5HT signaling could have an impact on early brain development...
July 17, 2017: Birth defects research
https://www.readbyqxmd.com/read/28713247/divergent-roles-of-central-serotonin-in-adult-hippocampal-neurogenesis
#8
REVIEW
Ning-Ning Song, Ying Huang, Xin Yu, Bing Lang, Yu-Qiang Ding, Lei Zhang
The central serotonin (5-HT) system is the main target of selective serotonin reuptake inhibitors (SSRIs), the first-line antidepressants widely used in current general practice. One of the prominent features of chronic SSRI treatment in rodents is the enhanced adult neurogenesis in the hippocampus, which has been proposed to contribute to antidepressant effects. Therefore, tremendous effort has been made to decipher how central 5-HT regulates adult hippocampal neurogenesis. In this paper, we review how changes in the central serotonergic system alter adult hippocampal neurogenesis...
2017: Frontiers in Cellular Neuroscience
https://www.readbyqxmd.com/read/28708853/selective-serotonin-reuptake-inhibitors-and-venlafaxine-in-pregnancy-changes-in-drug-disposition
#9
Andreas Austgulen Westin, Malin Brekke, Espen Molden, Eirik Skogvoll, Olav Spigset
BACKGROUND: Pregnancy may cause changes in drug disposition. The clinical consequences may be profound and even counterintuitive; in some cases pregnant women may need more than twice their usual drug dose in order to maintain therapeutic drug levels. For antidepressants, evidence on drug disposition in pregnancy is scarce. The aim of this study was to determine the effects of pregnancy on serum levels of selective serotonin reuptake inhibitors (SSRIs) and venlafaxine in a large and naturalistic patient material, in order to provide tentative dose recommendations for pregnant women...
2017: PloS One
https://www.readbyqxmd.com/read/28707591/new-generation-non-ssri-antidepressants-therapeutic-drug-monitoring-and-pharmacological
#10
Roberto Mandrioli, Michele Protti, Laura Mercolini
BACKGROUND: New-generation antidepressants (NGAs) are the latest additions to the clinician's arsenal in the fight against depression. After the introduction of selective serotonin reuptake inhibitors (SSRIs), a plethora of other groups followed, identified by their main mechanisms of activity: serotonin and norepinephrine reuptake inhibitors (SNRI); serotonin modulators and stimulators (SMS); serotonin antagonists and reuptake inhibitors (SARI); noradrenergic and selective serotonergic antidepressants (NaSSA); norepinephrine reuptake inhibitors (NeRI); serotonin, norepinephrine and dopamine reuptake inhibitors (SNDRI) or triple reuptake inhibitors (TRI); and melatonin and serotonin agonists (MaSA)...
July 12, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28705022/evaluation-of-dose-and-outcomes-for-pediatric-vilazodone-ingestions
#11
Christopher E Gaw, Henry A Spiller, Jason L Russell, Thiphalak Chounthirath, Gary A Smith
BACKGROUND: Selective serotonin reuptake inhibitor (SSRI) exposures among children younger than 6 years of age are generally well tolerated. Vilazodone is an SSRI with partial agonism at the 5-HT1A receptor with demonstrated clinical efficacy for depression whose off-label usage is likely to increase. Recent evidence suggests that unintentional ingestion of vilazodone in children under 6 years old is associated with more severe clinical effects than other SSRIs. We chose to evaluate dose and outcomes for pediatric vilazodone ingestions...
July 14, 2017: Clinical Toxicology
https://www.readbyqxmd.com/read/28702510/phosphodiesterase-5-inhibitors-for-premature-ejaculation-a-systematic-review-and-meta-analysis
#12
Marrissa Martyn-St James, Katy Cooper, Shijie Ren, Eva Kaltenthaler, K Dickinson, A Cantrell, Kevan Wylie, Leila Frodsham, Catherine Hood
CONTEXT: Phosphodiesterase-5 inhibitors (PDE5is) are prescribed off-label for the treatment of premature ejaculation (PE). OBJECTIVE: To systematically review the evidence from randomised controlled trials (RCTs) for PDE5is in the management of PE. EVIDENCE ACQUISITION: MEDLINE and other databases were searched to September 2015. Quality of RCTs was assessed. Intra-vaginal ejaculatory latency time (IELT) data were pooled in a meta-analysis...
February 2017: European Urology Focus
https://www.readbyqxmd.com/read/28702506/prenatal-depression-risk-factors-developmental-effects-and-interventions-a-review
#13
Tiffany Field
This narrative review based on a literature search in PubMed and PsycInfo on the two terms prenatal and antenatal depression includes empirical studies, reviews and meta-analyses that have been published during the last 5 years on risk factors, developmental effects and interventions for prenatal depression. Risk factor studies that met criteria feature demographic measures (lower socioeconomic status, less education, non-marital status, non-employment, less social support and health locus of control, unintended pregnancy, partner violence and history of child abuse) and physiological variables (cortisol, amylase, and pro-inflammatory cytokines and intrauterine artery resistance)...
February 2017: Journal of Pregnancy and Child Health
https://www.readbyqxmd.com/read/28677866/increased-incidence-of-non-alcoholic-fatty-liver-disease-in-male-rat-offspring-exposed-to-fluoxetine-during-fetal-and-neonatal-life-involves-the-nlrp3-inflammasome-and-augmented-de-novo-hepatic-lipogenesis
#14
Nicole E De Long, Daniel B Hardy, Noelle Ma, Alison C Holloway
Up to 10% of women take selective serotonin reuptake inhibitors (SSRI) during pregnancy. Children exposed to SSRIs in utero have an increased risk of being overweight suggesting that fetal exposure to SSRIs can cause permanent metabolic changes. We have previously shown in rats that fetal and neonatal exposure to the SSRI antidepressant fluoxetine results in metabolic perturbations including increased hepatic triglyceride content; a hallmark of non-alcoholic fatty liver disease (NAFLD). Therefore, the aim of this study was to identify the mechanism(s) underlying the fluoxetine-induced increase in intrahepatic triglyceride content...
July 5, 2017: Journal of Applied Toxicology: JAT
https://www.readbyqxmd.com/read/28677828/vortioxetine-for-depression-in-adults
#15
REVIEW
Markus Koesters, Giovanni Ostuzzi, Giuseppe Guaiana, Johanna Breilmann, Corrado Barbui
BACKGROUND: Major depressive disorder is a common mental disorder affecting a person's mind, behaviour and body. It is expressed as a variety of symptoms and is associated with substantial impairment. Despite a range of pharmacological and non-pharmacological treatment options, there is still room for improvement of the pharmacological treatment of depression in terms of efficacy and tolerability. The latest available antidepressant is vortioxetine. It is assumed that vortioxetine's antidepressant action is related to a direct modulation of serotonergic receptor activity and inhibition of the serotonin transporter...
July 5, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28675762/management-of-mood-and-anxiety-disorders-in-patients-receiving-opioid-agonist-therapy-review-and-meta-analysis
#16
REVIEW
Ahmed N Hassan, Aaron S Howe, Andriy V Samokhvalov, Bernard Le Foll, Tony P George
BACKGROUND AND OBJECTIVES: Patients with opioid use disorders and mood and anxiety symptoms have a variable prognosis. Few randomized controlled trials (RCTs) have evaluated treatment of depression or anxiety in patients receiving opioid agonist therapies (OAT). This review evaluates studies of pharmacotherapy/psychotherapy for treating symptoms of depression or anxiety in patients receiving OAT. METHODS: Public databases were searched for clinical trials of pharmacotherapy or psychotherapy for managing depression or anxiety symptoms in adults receiving OAT...
July 4, 2017: American Journal on Addictions
https://www.readbyqxmd.com/read/28674077/physicians-are-more-likely-than-non-physicians-to-use-brand-name-drugs-to-treat-their-chronic-conditions
#17
REVIEW
Mariana Carrera, Niels Skipper
BACKGROUND: Little is known about the treatments physicians choose for themselves compared with how they treat their patients. We determine if physicians prescribe different treatments to patients than to themselves. METHODS: Population-based cohort study from 2004 to 2012 examining prescription claims of all Danish primary care physicians (PCP; n=3088) and all other Danish adults (n=2 334 590) who received a first-time prescription from a PCP for a statin (n=455 586), calcium channel blocker (CCB, n=330 369), serotonin-norepinephrine/selective serotonin reuptake inhibitors (SN/SSRIs, n=423 740), proton pump inhibitor (PPI, n=671 965) or antihistamine (n=456 018)...
July 3, 2017: Journal of Epidemiology and Community Health
https://www.readbyqxmd.com/read/28666060/ssris-associated-with-decreased-risk-of-hepatocellular-carcinoma-a-population-based-case-control-study
#18
Hsiang-Lin Chan, Wei-Che Chiu, Vincent Chin-Hung Chen, Kuo-You Huang, Tsu-Nai Wang, Yena Lee, Roger S McIntyre, Tsai-Ching Hsu, Charles Tzu-Chi Lee, Bor-Show Tzang
BACKGROUND: Hepatocellular carcinoma (HCC) is the second leading cancer-related cause of mortality worldwide. Antidepressants, especially selective serotonin re-uptake inhibitors (SSRIs), are commonly used worldwide. Available evidence investigating the association between SSRIs use and HCC risk is limited. OBJECTIVE: he present study aimed to investigate if the effect of all kinds of SSRIs on HCC was the same or not using population-based study. METHODS: The nationwide population-based study herein using Taiwan's National Health Insurance Research Database included a total of 59,859 cases with HCC and 285,124 matched controls...
June 30, 2017: Psycho-oncology
https://www.readbyqxmd.com/read/28655626/differential-effects-of-perinatal-exposure-to-antidepressants-on-learning-and-memory-acoustic-startle-anxiety-and-open-field-activity-in-sprague-dawley-rats
#19
Jenna L N Sprowles, Jillian R Hufgard, Arnold Gutierrez, Rebecca A Bailey, Sarah A Jablonski, Michael T Williams, Charles V Vorhees
Most antidepressants inhibit monoamine reuptake. Selective serotonin (5-HT) reuptake inhibitors (SSRIs) act on the 5-HT transporter (SERT) whereas norepinephrine-dopamine reuptake inhibitors (NDRIs) act on the norepinephrine and dopamine transporters. Epidemiological reports link SSRI use during pregnancy to an increased prevalence of autism spectrum disorder (ASD). We previously showed that perinatal exposure to the SSRI citalopram (CIT) results in rodent offspring that exhibit a number of behaviors consistent with an ASD-like phenotype...
June 24, 2017: International Journal of Developmental Neuroscience
https://www.readbyqxmd.com/read/28654193/serotonin-transporter-gene-polymorphisms-and-ssri-tolerability-review-of-pharmacogenetic-evidence
#20
Jing Zhu, Michele Klein-Fedyshin, James M Stevenson
BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) are first-line pharmacotherapy for mood and anxiety disorders. The common mechanism of drugs in this class is antagonism of the serotonin transporter. Within the serotonin transporter gene SLC6A4, two polymorphic sites termed 5-HTTLPR and STin2 are proposed to have functional consequences and thus have been attractive candidates for pharmacogenetic studies of SSRI efficacy and tolerability studies. OBJECTIVE: This review summarizes approximately 15 years of study of these polymorphisms as they relate to SSRI tolerability phenotypes...
June 27, 2017: Pharmacotherapy
keyword
keyword
30573
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"